Protein Wnt-16 (WNT16)

Protein Wnt-16 is a secreted signaling ligand belonging to the Wnt family, playing a pivotal role in skeletal homeostasis, particularly in the regulation of cortical bone (NIH, 2021). It is primarily produced by cells of the osteoblast lineage and acts through both canonical (β-catenin-dependent) and non-canonical (e.g., JNK) signaling pathways (Frontiers in Endocrinology, 2022). In the bone microenvironment, Wnt-16 promotes osteoblast differentiation and survival while simultaneously inhibiting osteoclastogenesis through direct action on progenitors and the upregulation of osteoprotegerin (OPG) (Nature Medicine, 2014). Genetic studies, including large-scale GWAS, have identified WNT16 as a major determinant of bone mineral density, cortical thickness, and the risk of non-vertebral fractures (PLoS Genetics, 2012). Due to its bone-specific expression and potent anabolic and anti-resorptive effects, it is considered a high-priority therapeutic target for osteoporosis (Frontiers in Aging, 2026). Current pharmacological strategies under investigation include the use of Notum inhibitors to prevent the deacylation and inactivation of Wnt-16, thereby enhancing its local signaling activity (NIH, 2019).

Other names

WNT16Wingless-type MMTV integration site family member 16Wnt16/β-catenin signaling axis

Activation of canonical β-catenin and non-canonical JNK signaling pathways to stimulate osteoblast activity and suppress osteoclast-mediated bone resorption (Nature Medicine, 2014; Frontiers in Endocrinology, 2022).